

Network Health Plan/Network Health Insurance Corporation  
Genetic Testing Authorization Requirements

Revised 12/31/2009

Prior Authorization Required CPT Code	Genetic Test Code Description
83890	Molecular diagnosis, molecular isolation or extraction, each nucleic acid type (ie. DNA or RNA)
83891	isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie. DNA or RNA)
83892	enzymatic digestion, each enzyme treatment
83893	dot/slot blot production, each nucleic acid preparation
83894	separation by gel electrophoresis, each nucleic acid preparation
83896	nucleic acid probe, each
83897	nucleic acid transfer (eg, Southern, Northern), each nucleic acid preparation
83898	amplification, target, each nucleic acid sequence
83900	amplification, target, multiplex, first 2 nucleic acid sequences
83901	amplification, target, multiplex, each additional nucleic acid sequence beyond 2 (add on, list separately)
83902	reverse transcription
83903	mutation scanning by physical properties; heteroduplex, denaturing gradient gel electrophoresis, single segment, each
83904	mutation identification by sequencing, single segment, each
83905	mutation identification by allele specific transcription, single segment, each
83906	mutation identification by allele specific translation, single segment, each
83907	lysis of cells prior to nucleic acid extraction, each specimen
83908	amplification, signal, each nucleic acid sequence
83909	separation and identification by high resolution technique (eg. Capillary electrophoresis), each preparation
83912	interpretation and report
83913	RNA stabilization
83914	Mutation identification by enzymatic ligation or primer extension, single segment, each, single base chain extension or allele specific primer extension
88230	cytogenetic study; Tissue culture for non neoplastic disorder
88233	cytogenetic study; skin or other solid tissue biopsy
88235	cytogenetic study; amniotic fluid or chorionic villus cells
88237	cytogenetic study; Tissue culture for neoplastic disorders, bone marrow, blood cells
88239	cytogenetic study; solid tumor
88240	cytogenetic study; cryopreservation, freezing and storage cells,
88241	cytogenetic study; thawing and expansion of frozen cells, each aliquot
88245	Chromosome analysis of breakage syndromes; baseline Sister Chromatid Exchange; 20-25 cells
88248	baseline breakage, score 50-100 cells, count 20 cells, 2 karyotypes
88249	score 100 cells, clastogen stress

Network Health Plan/Network Health Insurance Corporation  
Genetic Testing Authorization Requirements

88261	Chromosome analysis; count 5 cells, 1 karyotype, with banding
88262	count 15-20 cells, 2 karyotypes, with banding
88263	count 45 cells for mosaicism, 2 karyotypes, with banding
88264	analyze 20-25 cells
88267	Chromosome analysis, amniotic fluid or choionic villus, count 15 cells, 1 karotype, with banding
88269	Chromosome analysis, in situ for amniotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding
88271	Molecular cytogenetics; DNA probe, each (eg FISH)
88272	chromosomal in situ hybridization, analyze 3-5 cells
88273	chromosomal in situ hybridization, analyze 10-30 cells
88274	interphase in situ hybridization, analyze 25-99 cells
88275	interphase in situ hybridization, analyze 100-300 cells
88280	Chromosome analysis; additional karyotypes, each study
88283	additional specialized banding technique (eg. NOR, C-banding)
88285	additional cells counted, each study
88289	additional high resolution study
88291	Cytogenetics and molecular cytogenetics, interpretation and report
88299	unlisted cytogenetic study
88384	Array-based evaluation of multiple molecular probes; 11 through 50 probes
88385	51 through 250 probes
88386	251-500 probes
88387	Macroscopic examination, dissection and preparation of tissue for non-microscopic analytical studies (eg, nucleic acid-based molecular studies); in conjunction with a touch imprint, intraoperative consultation, or frozen section, each tissue preparation (eg, a single lymph node) (List separately in addition to code for primary procedure
88388	Macroscopic examination, dissection and preparation of tissue for non-microscopic analytical studies (eg, nucleic acid-based molecular studies); each tissue preparation (eg, a single lymph node)
D0421	Genetic testing for suseptibility to oral diseases
S3800	Genetic testing for amyotrophic lateral sclerosis (ALS)
S3818	Complete gene sequence analysis; BRCA1 gene
S3819	Complete gene sequence analysis; BRCA2 gene
S3820	Complete BRCA1 and BRCA2 gene sequence analysis for susceptibility to breast and ovarian cancer
S3822	Single mutation analysis (in individual with a known BRCA1 or BRCA2 mutation in the family) for susceptibility to breast and ovarian cancer.
S3823	Three mutation BRCA1 and BRCA2 analysis for susceptibility to breast and ovarian cancer in Ashkenazi individuals
S3828	Complete gene sequence analysis; MLH1 gene
S3829	Complete gene sequence analysis; MLH2 gene

Network Health Plan/Network Health Insurance Corporation  
Genetic Testing Authorization Requirements

S3830	Complete MLH1 and MLH2 gene sequence analysis for hereditary nonpolyposis colorectal cancer (HNPCC) genetic testing
S3831	Single mutation analysis (in individual with a known MLH1 and MLH2 mutation in the family) for hereditary nonpolyposis colorectal cancer (HNPCC) genetic testing
S3833	Complete APC gene sequence analysis for susceptibility to familial adenomatous polyposis (FAP) and attenuated FAP
S3834	Single mutation analysis (in individual with a known APC mutation in the family) for susceptibility to familial adenomatous polyposis (FAP) and attenuated FAP
S3835	Complete gene sequence analysis for cystic fibrosis genetic testing
S3837	Complete gene sequence analysis for hemochromatosis genetic testing
S3840	DNA analysis for germline mutations of the RET proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
S3841	Genetic testing for retinoblastoma
S3842	Genetic testing for Von Hippel-Lindau disease
S3844	DNA analysis of the connexin 26 gene (GJB2) for susceptibility to congenital, profound deafness
S3845	Genetic testing for alpha-thalassemia
S3846	Genetic testing for hemoglobin E beta-thalassemia
S3847	Genetic testing for Tay-Sachs disease
S3848	Genetic testing for Gaucher disease
S3849	Genetic testing for Niemann-Pick disease
S3850	Genetic testing for sickle cell anemia
S3851	Genetic testing for Canavan disease
S3852	DNA analysis for APOE epsilon 4 allele for susceptibility to Alzheimer's disease
S3853	Genetic testing for myotonic muscular dystrophy
S3854	Gene expression profiling panel for use in the management of breast cancer treatment
S3855	Genetic testing for the detection of mutations in the presenilin-1 gene
S3860	Genetic testing, comprehensive cardiac ion channel analysis for variants in 5 major cardiac ion channel genes for individuals with high index suspicion for familial long QT syndrome (LQTS) or related syndromes
S3861	Genetic testing, sodium channel, voltage-gated, Type V, alpha subunit (SCN5A) and variants for suspected Brugada Syndrome
S3862	Genetic testing, family-specific ion channel analysis, for blood-relatives of individuals (index case) who have previously tested positive for a genetic variant of a cardiac ion channel syndrome using either one of the above configurations or confirmed results from another laboratory.
S3865	Comprehensive gene sequence analysis for hypertrophic cardiomyopathy
S3866	Genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (HCM) in an individual with a known HCM mutation in the family

Network Health Plan/Network Health Insurance Corporation  
Genetic Testing Authorization Requirements

S3870	Comparative genomic hybridization (CGH) microarray testing for developmental delay, autism spectrum disorder and/or mental retardation
S3890	DNA analysis, fecal, for colorectal cancer screening







Network Health Plan/Network Health Insurance Corporation  
Genetic Testing Authorization Requirements

5/27/2009 (new code)